Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Biochemistry, Kwara State University, Malete, Nigeria.
Int J Pharm. 2024 Nov 15;665:124658. doi: 10.1016/j.ijpharm.2024.124658. Epub 2024 Sep 3.
Erythrocytes have gained popularity as a natural option for in vivo drug delivery due to their advantages, which include lengthy circulation times, biocompatibility, and biodegradability. Consequently, the drug's pharmacokinetics and pharmacodynamics in red blood cells can be considerably up the dosage. Here, we provide an overview of the erythrocyte membrane's structure and discuss the characteristics of erythrocytes that influence their suitability as carrier systems. We also cover current developments in the erythrocyte-based nanocarrier, which could be used for both active and passive targeting of disease tissues, particularly those of the reticuloendothelial system (RES) and cancer tissues. We also go over the most recent discoveries about the in vivo and in vitro uses of erythrocytes for medicinal and diagnostic purposes. Moreover, the clinical relevance of erythrocytes is discussed in order to improve comprehension and enable the potential use of erythrocyte carriers in the management of various disorders.
红细胞由于其具有循环时间长、生物相容性和可生物降解等优点，已成为体内药物递送的一种自然选择。因此，药物在红细胞中的药代动力学和药效学可以大大提高剂量。在这里，我们提供了红细胞膜结构的概述，并讨论了影响红细胞作为载体系统适用性的特征。我们还介绍了基于红细胞的纳米载体的最新进展，这些载体可用于主动和被动靶向疾病组织，特别是网状内皮系统（RES）和癌症组织。我们还回顾了红细胞在医学和诊断用途方面的最新体内和体外应用发现。此外，还讨论了红细胞的临床相关性，以提高认识并使红细胞载体在各种疾病的治疗中的潜在应用成为可能。
